Investigators initiate seven trials in Japan of Cytori's stem cells
US company Cytori has been informed that seven new investigator-initiated clinical studies covering a range of indications in Japan using adipose-derived regenerative cells have been approved by local ethical committees.
Cytori, which will not sponsor these studies, will continue to work with country authorities, such as the Ministry of Health, Labor and Welfare in Japan, to obtain specific regulatory approvals for its products. Data from these studies may benefit the firm by establishing and broadening the use of its Celution System platform, which is currently sold in more than 30 countries around the world.
Investigator-initiated studies are sponsored entirely by each hospital, which independently oversees data monitoring and reporting.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze